Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | OTC | P00480 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL28868287 | 1.00 | GSR (0.38) | GSRPRCPGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL29151521 | 0.97 | GSR (0.36) | GSRPRCPGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL3195919 | 0.94 | GSR (0.33) | GSRPRCPGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL28628260 | 0.94 | MEN1 (0.36) | GSRPRCPGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL28818309 | 0.94 | GSR (0.37) | GSRPRCPGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL28469088 | 0.93 | PRCP (0.35) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL29206209 | 0.93 | PRCP (0.35) | PRCPOTCDDAH1NOS3NOS1 | |
| Arginine SCHEMBL6369693 | 0.93 | PRCP (0.37) | PRCPOTCDDAH1TDP1NOS3 | |
| Arginine SCHEMBL27501016 | 0.93 | GSR (0.40) | GSRPRCPGNAI3GNAO1GNAI1 | |
| Arginine SCHEMBL6045042 | 0.93 | GSR (0.43) | GSRPRCPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530641-B1 | DNA EXPRESSION CONSTRUCT FOR MULTIPLE GENE EXPRESSION | MOLOGEN AG (DE) | 2007-01-24 | — | — | EP | claimed |
| EP-1553977-B1 | VACCINE AGAINST INFECTIONS CAUSED BY ONCOVIRUSES SUCH AS THE FELINE LEUCOSIS VIRUS OF CATS | MOLOGEN AG (DE) | 2006-08-09 | — | — | EP | claimed |
| EP-1432439-B1 | MEANS FOR IMPROVING IMMUNE RESPONSE | MOLOGEN AG (DE) | 2005-12-07 | — | — | EP | claimed |
| CN-1564694-A | Method for improving immune response | MOLOGEN FORSCHUNGS ENTWICKLUNG (DE) | 2005-01-12 | — | — | CN | claimed |
| US-20040235772-A1 | DNA expression construct for the treatment of infections with leishmaniasis | MOLOGEN AG (DE) | 2004-11-25 | — | — | US | claimed |
| US-20040235771-A1 | Means for eliciting an immune response and a method therefor | MOLOGEN AG (DE) | 2004-11-25 | — | — | US | claimed |
| US-20230116385-A1 | COMPOSITION OF A THERAPEUTIC OLIGOMER | Sachi Bioworks Inc. (US) | 2023-04-13 | — | — | US | disclosed |
| US-10752900-B2 | Oligonucleotides for modulating gene expression and uses thereof | BIOGENERA S.P.A. (IT) | 2020-08-25 | — | — | US | disclosed |
| US-20180282731-A1 | OLIGONUCLEOTIDES FOR MODULATING GENE EXPRESSION AND USES THEREOF | BIOGENERA S.P.A. (IT) | 2018-10-04 | — | — | US | disclosed |
| US-10023867-B2 | Oligonucleotides for modulating gene expression and uses thereof | BIOGENERA S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| EP-2817407-B1 | OLIGONUCLEOTIDES FOR MODULATING GENE EXPRESSION AND USES THEREOF | BIOGENERA S P A (IT) | 2017-09-06 | — | — | EP | disclosed |
| US-20160040166-A1 | OLIGONUCLEOTIDES FOR MODULATING GENE EXPRESSION AND USES THEREOF | BIOGENERA S.P.A. (IT) | 2016-02-11 | — | — | US | disclosed |
| US-20150328308-A1 | Means for Eliciting an Immune Response and a Method Transfer | MOLOGEN AG (DE) | 2015-11-19 | — | — | US | disclosed |
| WO-1999010508-A1 | CHIMERIC TRANSCRIPTIONAL ACTIVATORS AND COMPOSITIONS AND USES RELATED THERETO | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010510-A2 | FUSION PROTEINS COMPRISING A DIMERIZATION, TRIMERIZATION OR TETRAMERIZATION DOMAIN AND AN ADDITIONAL HETEROLOGOUS TRANSCRIPTION ACTIVATION, TRANSCRIPTION REPRESSION, DNA BINDING OR LIGAND BINDING DOMAIN | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0799243-A4 | p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS | WISTAR INST (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5721340-A | PROTEINS UNABLE TO HETERO-OLIGOMERIZE WITH WILD-TYPE P53 OR TUMOR-DERIVED MUTANT P53 PROTEINS | THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0799243-A1 | p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5573925-A | P53 proteins with altered tetramerization domains | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996016989-A1 | p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 1996-06-06 | — | — | WO | disclosed |